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ABSTRACT 15 
The objectives of the present study were to determine effects of jugular vein infusions of 16 
glucagon like peptide-1 (GLP-1) and dietary fat inclusion on dry matter intake, nutrient 17 
digestibility and hypothalamic mRNA concentration of neuropeptide Y, agouti related peptide, 18 
and proopiomelanocortin in growing sheep. Thirty six wethers were used (40.7 ± 3.3 kg BW). 19 
Treatments were a control diet (n = 11), dietary addition (6% of dry matter) of Ca salts of palm 20 
oil fatty acids (n = 12), or 6-d jugular vein infusions of 0.155 μg/kg body weight/day of GLP-1 21 
(n = 11). Hormone concentrations were measured in jugular vein plasma from samples taken on 22 
day 1, 4 and 6. On d 7, the wethers were slaughtered for hypothalamus collection to measure 23 
mRNA concentration. The dietary addition of 6% of Ca salts of palm oil increased plasma GLP-24 
1 concentration (P < 0.01) and decreased dry matter intake on day 1, but not on day 6 (time x 25 
treatment interaction, P < 0.05). The infusion of GLP-1 did not change dry matter intake (P > 26 
0.20), but increased neutral detergent fibre digestibility (P < 0.01). In conclusion, glucagon like 27 
peptide-1 infusion or feeding fat did not decrease dry matter intake or affect hypothalamic 28 
neuropeptide mRNA concentrations of sheep.  29 
RÉSUMÉ 30 
Les objectifs de cette étude étaient d'évaluer l'effet des infusions dans la veine jugulaire 31 
du glucagon-like peptide-1 (GLP-1) et de l’addition alimentaire de matières grasses sur 32 
l’ingestion de matière sèche (IMS), la digestibilité des nutriments et la concentration de l'ARNm 33 
dans l'hypothalamus du neuropeptide Y (NPY), de la protéine agoutie (AgRP), et de la pro-34 
opiomélanocortine (POMC). Trente-six béliers ont été utilisés (40.7 ± 3.3 kg). Les traitements 35 
ont été un régime témoin (n 11), addition alimentaire (6% de la MS) de sels de Ca d’acides 36 
palmitiques (n12), ou 6 jours (j) d’infusion dans la veine jugulaire de 0.155 μg/kg PC/j de GLP-1 37 
(n 11). Les concentrations d'hormones ont été mesurées dans le plasma de la veine jugulaire des 38 
échantillons prélevés le jour 1, 4 et 6. Le jour 7, les béliers ont été abattus pour la collecte de 39 
l'hypothalamus pour mesurer la concentration de l'ARNm de NPY, AgRP et POMC. L'ajout de 40 
6% de sels de Ca d’acides palmitiques a augmenté la concentration plasmatique de GLP-1 (P 41 
<0,01) et diminué l’lMS du j 1, mais pas du j 6 (interaction de temps x traitement, P <0,05). 42 
L'infusion de GLP-1 n'a pas changé l’IMS (P> 0,20), mais a augmenté la digestibilité des fibres 43 
au détergent neutre (P <0,01). Il n'y avait aucune différence dans la concentration de l'ARNm de 44 
NPY, AgRP ou POMC en raison de l’infusion de GLP-1 ou de l’addition alimentaire de matières 45 
grasses. En conclusion, la seule perfusion intraveineuse de GLP-1 n'a pas diminué l’IMS chez les 46 
ovins en croissance. 47 
Mots-clés: glucagon-like peptide-1, ingestion de matière sèche, mouton, neuropeptides 48 
hypothalamiques 49 
 50 
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 58 
INTRODUCTION 59 
In nonruminants, increasing plasma glucagon-like peptide-1(7, 36) amide (GLP-1) 60 
concentration decreases feed intake (Turton et al., 1996). In ruminants, an increase in plasma 61 
GLP-1 concentration has been associated with a decrease in dry matter intake (DMI) when fat 62 
was added to the diet (Relling and Reynolds, 2007; Bradford et al., 2008, Relling et al., 2010). 63 
Also, intrajugular infusion of GLP-1 in wethers decreased DMI to a similar extent as feeding fat 64 
(Relling et al., 2011). However, the central mechanism of how GLP-1 regulates feed intake is not 65 
certain. In fasted rats, intracerebroventricular (ICV) infusion of GLP-1 did not change mRNA 66 
concentration for neuropeptide Y (NPY) (Turton et al., 1996). In contrast, Seo et al. (2008) 67 
reported that ICV infusion of GLP-1 decreased NPY and agouti-related peptide (AgRP) and 68 
increased proopiomelanocortin (POMC) mRNA concentration in the hypothalamus of fasted 69 
rats. In ruminants, in vitro culture of sheep hypothalamus in media containing GLP-1 did not 70 
change the relative concentration of NPY, AgRP or POMC mRNA (Relling et al., 2012). 71 
However, an increase in NPY and AgRP mRNA was associated with an increase in plasma GLP-72 
1 concentration and a decrease in DMI when fat was fed to growing lambs (Relling et al., 2010). 73 
There is a paucity of information on the effect of intravenous infusion of GLP-1 on the mRNA 74 
concentration for hypothalamic neuropeptides associated with DMI regulation and its association 75 
with DMI. Based on the cited literature, we hypothesized that increases in plasma GLP-1 76 
concentration within physiological concentrations, due to continuous jugular vein infusion of 77 
GLP-1 or by feeding fat, would decrease DMI. We also hypothesized that decreases in DMI 78 
would be associated with changes in hypothalamic gene expression of NPY, AgRP and POMC. 79 
Therefore the objective of our study was to determine the effect of a continuous jugular vein 80 
infusion of GLP-1 or feeding fat on plasma GLP-1 concentration, DMI, and mRNA 81 
concentration of the neuropeptides NPY, AgRP and POMC in growing wethers.  82 
 83 
MATERIALS AND METHODS 84 
Animal care followed guidelines recommended in the Guide for the Care and Use of 85 
Agricultural Animals in Agricultural Research and Teaching (FASS, 1998) and procedures used 86 
were approved by the Animal Care Committee of the Ohio Agricultural Research and 87 
Development Center. 88 
Three weeks before the start of the experiment, 36 Targhee x Hampshire wethers  (40.7 ± 89 
3.3 kg BW) were fed a pelleted control diet (Table 1) formulated to meet nutrient  requirements 90 
of growing lambs according to the National Research Council (NRC, 1985). The wethers were 91 
grouped by weight and housed in three pens with 12 wethers each. Daily rations were provided 92 
at 0800 h, and wethers were fed for ad libitum intake of dry matter (DM, 10% refusal) 93 
throughout the study. Treatments were 7 d of: 1) control diet (CONT); 2) supplemental dietary 94 
fat (Ca-salts of palm oil) at 6% of ration DM (FAT); 3) control diet with intravenous GLP-1 95 
(GLP-1; 0.155 μg/kg BW/d of GLP-1(7-36) amide H6795, Bachem California Inc, CA) in 1 L of 96 
saline (0.9% NaCl). These treatments were selected based on previous results in growing lambs 97 
(Relling et al., 2011), where the infusion of 0.155 μg/kg BW/d of GLP-1(7-36) amide produced a 98 
similar increase in plasma GLP-1 concentration as adding 6% supplemental fat to the diet. The 99 
wethers on the CONT and FAT treatments received a control intravenous infusion of 1 L of 100 
sterile saline solution daily. The hormone solutions and the saline solutions were made and 101 
infused as described in Relling et al. (2011).  102 
The experiment was conducted as a completely randomized block design. Each of the three 103 
groups of wethers was considered as a block. Within each block, the 12 wethers were allocated randomly 104 
to one of the three treatments (n = 4/treatment). Beginning two weeks before the experiment, the wethers 105 
were housed in individual pens. Wethers fed supplemented fat were adapted to fat supplementation for 2 106 
wk before sampling began, with an amount equal to 2% of ration DM fed on day 1 of the adaptation 107 
period, 4% on day 2 and 3, and 6% from day 4 onwards. One week before the experiment started, the 108 
lambs were moved into metabolic crates as described previously (Murphy et al., 1994) and adapted to 109 
procedures used during the sampling week, including feeding, removal of orts, and changing of fecal 110 
collection containers. Forty five hours before the experiment started, jugular vein catheters were 111 
established as described previously (Relling et al., 2011). Two animals experienced a drop in DMI to less 112 
than 50% of the previous day’s intake when lambs were moved into the metabolic crates. Therefore, 113 
before the infusions started, one wether on the control treatment and one wether on the GLP-1 treatment 114 
were removed from the experiment. The continuous infusions were done as described previously (Relling 115 
et al., 2011) and started at 1000 h on day 1 of the experimental period. Briefly, GLP-1 solutions were  116 
prepared using 1 L of sterile saline solution (9 g/L of NaCl; VWR International, West Chester, PA). The 117 
liter of saline solution was infused at a rate of 0.725 ml/min during 23 h. The wethers fed the 118 
control and the fat supplemented diets were intravenously infused with 1 L of sterile saline solution (9 g/L 119 
of NaCl). The targeted dose of GLP-1 infused was calculated using a single compartment, first-order 120 
kinetic hormone degradation model, based on the equation: 121 
Increase in hormone concentration x 0.693/half life. 122 
The half life used for this equation was 5 min for GLP-1 (Perfetti and Merkel, 2000). The 123 
value, 0.693, is the slope of the first order degradation. The target increase for GLP-1 was based 124 
on a previous report (Relling et al., 2011).  125 
The bottles with sterile saline solution and those with GLP-1 in solution were kept on ice 126 
during the infusion. The infusion line from the bottle to the animal was sterilized using an 127 
ethylene oxide (EtO) gas (Cole-Parmer, Vernon Hills, IL). The connection between the bottle 128 
with the infusion and the infusion line included a sterile 0.45 μm syringe filter (Whatman 129 
International Ltd, Florham Park, NJ). 130 
  Between the end of each day’s infusion and the start of the following day, the infusion 131 
lines were flushed with sterile saline solution (9 g/L of NaCl) and the filters were changed. Feed 132 
was offered daily at 1300 h and the refusals were removed and weighed 23 h later at 1200 h. For 133 
digestibility and plasma samples, samples were collected and processed as described previously 134 
(Relling et al., 2011). Briefly, to measure digestibility, total fecal collection was performed daily 135 
during the last 5 d of each experimental period. Five percent of the total daily feces was collected 136 
and composited for analysis of DM (100°C oven for 24 h), neutral detergent fibre (NDF, 137 
(Ankom200 Fiber Analyzer, ANKOM Technology, Fairport, NY), crude protein (CP, Kjeldahl N 138 
x 6.25), fatty acids (FA, Sukhija and Palmquist, 1988), and ash (AOAC 1990) concentration. 139 
Blood samples (10 ml) were taken 6 and 8 h after feed was offered on day 1, 4, and 6 of each 140 
experimental period. Blood samples were immediately transferred into polypropylene tubes 141 
containing solutions of disodium EDTA and benzamidine HCl (1.6 mg and 4.7 mg/ml blood, 142 
respectively) and placed on ice. After centrifugation for 25 min at 1800 x g and 4°C, plasma was 143 
partitioned into individual polypropylene tubes for each analysis to be performed, flash frozen 144 
using liquid N2 within 40 min of sample collection, and stored at -80°C until analyzed. Samples 145 
from the infusate were taken after the in line filters during the first sampling time on day 4 to 146 
confirm that the infusate contained the correct concentration of GLP-1.   Measured GLP-1 147 
concentrations in the infusate were within 98.2% (±3.7, P = 0.798) of targeted concentrations. 148 
Concentrations of insulin and GLP-1 were measured using radioimmunoassays as described 149 
previously (Reynolds et al., 1989; Benson and Reynolds, 2001). The intra-assay CV averaged 150 
less than 12.5% for insulin and less than 11% for GLP-1.  Minimum sensitivities (90% of zero 151 
standard binding) of the insulin and GLP-1 assays were 0.0027 and 0.001 ng/tube, respectively. 152 
Plasma glucose concentration was measured using a colorimetric assay (#1070 Glucose Trinder, 153 
Stanbio Laboratory, Boerne, TX). Plasma NEFA concentration was measured using microtiter 154 
plates and a plate reader in a two-reaction, enzyme based assay (Wako Chemicals USA, 155 
Richmond, VA) as described by Johnson and Peters (1993). 156 
The morning of the seventh day of infusions, the lambs were transported 165 km 157 
(transport time was 100 min) to an abattoir for hypothalamus collection.  It has been previously 158 
reported (Relling et al., 2010) that there were no effects of the same transportation routine on the 159 
mRNA concentration for the same genes in the hypothalamus of similar lambs (Relling et al., 160 
2010). The hypothalamus was collected within 1 hour after arrival to the slaughter house as 161 
described by Relling et al. (2010). During hypothalamus collection, one sample from a lamb on 162 
the GLP-1 treatment was lost due to damage of the brain caused by the captive bolt used at 163 
slaughter.  164 
To measure hypothalamic mRNA concentration for NPY, AgRP and POMC, the protocol 165 
and primers used were as described by Relling et al. (2010). Briefly, RNA was extracted with 166 
TRIzol® (Invitrogen Carlsbad, CA) using procedures recommended by the manufacturer. 167 
Concentration of RNA was determined by measuring absorbance at 260 nm. Reverse 168 
transcription (RT) PCR was performed as described by Ndiaye et al. (2008). The relative mRNA 169 
concentration of NPY, AgRP, and POMC were determined by quantitative RT PCR using the 170 
DNA Engine Monitor 2 (BioRad Laboratories, Hercules, CA). Primers for NPY, AgRP and 171 
POMC were validated in sheep hypothalamic tissue by cDNA purification and sequencing. 172 
Oligonucleotide primers for NPY, AgRP and POMC were obtained from Qiagen Operon 173 
Biotechnologies (Alameda, CA). The primer sequences used are described on Table 2. The 174 
quantitative RT PCR was run for a maximum of 35 cycles, under the following conditions: 175 
denaturing at 94° C for 30 s, annealing at 60° C for 60 s, and extension at 72° C for 60 s. 176 
Concentrations of NPY, AgRP and POMC were normalized to cyclophilin B mRNA expression 177 
in the same sample to determine the relative mRNA concentrations of NPY, AgRP, and POMC. 178 
Homologous standard curves were prepared from purified NPY, AgRP, and POMC cDNA PCR 179 
products to calculate the steady-state concentration of NPY, AgRP, and POMC mRNA in 180 
triplicate wells for each sample. The PCR amplification products were electrophoretically 181 
separated on 1.5% agarose gels and visualized with ethidium bromide. For initial validation, the 182 
specific band corresponding to the size of the expected NPY, AgRP, and POMC cDNA fragment 183 
was cut and purified using the QIAquick Gel Extraction Kit (Qiagen Sciences) for sequence 184 
confirmation. 185 
The data were statistically analyzed as a complete randomized block design with repeated 186 
measurements in time using the MIXED procedure of SAS (Version 9.1, SAS Institute, Cary, 187 
NC) and a model testing the random effects of wether and block, and the fixed effect of 188 
treatment and time and their interaction. The two daily plasma samples for hormones and 189 
metabolites from the three days of sampling in each experimental period were analyzed in the lab 190 
individually but the average for each day was used in the statistical analysis. For digestibility and 191 
mRNA concentration data, a similar statistical model was used without the effect of time and its 192 
interaction. When the time by treatment interaction was significant, the slice option of SAS was 193 
used for separation of means. Fisher's protected LSD test was used for means separation at a P 194 
value of 0.05, for digestibility, mRNA concentration, and when the time by treatment interaction 195 
was not significant (P > 0.10). Trends were discussed for P values between 0.05 and 0.10. 196 
 197 
RESULTS 198 
  There was a time by treatment interaction for DMI (P < 0.05; Figure 1), due to a greater 199 
DMI for GLP-1 and control-fed wethers compared with the fat-fed wethers on day 1, but no 200 
difference in DMI on day 6 for the three treatments. Metabolizable energy intake and 201 
digestibility of DM, CP, FA and organic matter (OM) was not different among the treatments (P 202 
> 0.10; Table 3). The addition of dietary fat decreased (P < 0.05) and there was a trend for GLP-203 
1 infusion to increase (P < 0.10) NDF digestibility compared with control fed wethers. Feeding 204 
fat or GLP-1 infusion did not change plasma concentrations of insulin and glucose (P > 0.30; 205 
Table 4) compared with the control wethers. Compared with control wethers, plasma GLP-1 206 
(Figure 2) and NEFA concentrations (Table 4) increased due to additional dietary fat (P < 0.05), 207 
but were not affected (P > 0.10) by GLP-1 infusion. Hypothalamic mRNA concentrations of 208 
NPY, AgRP and POMC were not affected by treatments (P > 0.25; Table 5). 209 
 DISCUSSION  210 
 The objective of the experiment was to infuse GLP-1 to achieve a similar plasma 211 
concentration as had been previously observed in response to feeding supplemental fat (Relling 212 
et al., 2011). We hypothesized that continuous jugular vein infusion of GLP-1 (within 213 
physiological concentrations) or feeding fat would decrease DMI. A second objective was to 214 
elucidate if the decrease in DMI typically observed when feeding fat was associated with 215 
changes in mRNA concentration of the neuropeptides NPY, AgRP and POMC in response to 216 
GLP-1 or by other non GLP-1 effects of feeding fat.  217 
 In the present study there was an interaction of treatments and days on DMI. Similar 218 
amounts of fat or GLP-1 infusion tended to decrease DMI in sheep in previous studies compared 219 
with control animals (Reynolds et al., 2006; Relling et al., 2010; Relling et al., 2011). In the 220 
present study, wethers fed fat had a smaller DMI on day 1 compared with control wethers. 221 
However, fat-fed wethers had an increase in DMI over time, such that by day 6 they had the 222 
same DMI as control wethers. Also, wethers infused with GLP-1 started on day 1 with a greater 223 
DMI compared with control wethers, and then their DMI tended to decrease toward day 3. As 224 
observed in the present study, Relling et al. (2011) reported that dietary inclusion of 6% fat 225 
tended to decrease NDF digestibility in sheep. Harvatine and Allen (2006) reported that the 226 
inclusion of fat in dairy cow diets decreased ruminal digestibility, but not total tract digestibility 227 
of NDF. A possible reason for the decrease in NDF digestibility in wethers fed diets containing 228 
increased fat in the present experiment could be because of increased rate of passage, as 229 
observed in sheep fed a similar fat supplemented diet (Relling et al., 2011); however, rate of 230 
passage was not measured in the current experiment. The infusion of GLP-1 tended to increase 231 
NDF digestibility compared with control-fed wethers. Our assumption was that an increase in 232 
NDF digestibility with GLP-1 infusion would be due to a decrease in gut motility and increased 233 
retention time of fibre in the rumen and/or hindgut, allowing more time for NDF fermentation by 234 
gut microbes. Results of the present study may be because of an increase in digesta retention 235 
time, but in a previous study (Relling et al., 2011) GLP-1 infusion at the same rate had no effect 236 
on rate of passage or NDF digestibility. In addition, the effect of fat on NDF digestibility 237 
observed in the present study was opposite to the effect of GLP-1 infusion, but feeding fat 238 
increased plasma concentration of GLP-1. These observations suggest that the effects of fat on 239 
NDF digestibility were not due to an increase in GLP-1 concentration for the fat treatment.  240 
Feeding fat increased plasma GLP-1 concentration, but the infusion of GLP-1 did not 241 
change plasma GLP-1 concentration compared with control-fed wethers. As shown in Figure 2, 242 
infusion of GLP-1 tended to increase plasma GLP-1 concentration on day 4 but then 243 
concentrations decreased on day 6. The lack of response of plasma GLP-1 concentration to GLP-244 
1 infusion could be due to a decrease in endogenous secretion into blood, an increased clearance 245 
rate, or both; however, we are not aware of studies that can support this assumption. This lack of 246 
response of plasma GLP-1 concentration was unexpected and may in part explain the lack of 247 
effects of GLP-1 infusion on DMI.  However, this lack of response in the GLP-1 infused wethers 248 
does not explain the observed increase in NDF digestibility.  249 
As has been observed previously, feeding supplemental fat increased plasma NEFA 250 
concentration (Gagliostro and Chilliard, 1991; Relling and Reynolds, 2007), perhaps due to a 251 
higher plasma concentration of lipoproteins (Gagliostro and Chilliard, 1991). This increase in 252 
plasma NEFA occurred concurrently with an increase in plasma GLP-1 concentration. However, 253 
infusion of GLP-1 did not increase plasma NEFA concentration. The lack of response on plasma 254 
NEFA concentration observed in the present study and observed previously (Relling et al., 255 
2011), suggests GLP-1 infusion does not change plasma NEFA concentration. 256 
In the present study, there were no differences in hypothalamic mRNA concentrations for 257 
the neuropeptides NPY, AgRP and POMC due to feeding fat or GLP-1 infusion. It has been 258 
observed that feeding the same amount of supplemental fat deceases DMI and increases NPY 259 
and AgRP (Relling et al., 2011) in growing wethers. The reason for the lack of response of 260 
mRNA concentrations for hypothalamic neuropeptides to supplemental fat in the present 261 
experiment is not certain. In the case of the GLP-1 infusion treatment, it may have been due to 262 
the inability to achieve a sustained increase in plasma concentrations with the dose infused. 263 
However, the lack of response on hypothalamic neuropeptide mRNA concentration is also 264 
reflected by the lack of differences on DMI observed on day 6. Despite this lack of response of 265 
mRNA concentration, the actual neuropeptide concentration or secretion was not measured. It 266 
has been observed that changes in the mRNA concentration are associated with changes in the 267 
peptide concentration (Kameda et al., 2001); however, we are not aware of any study which has 268 
measured the association between mRNA concentration of the neuropeptide and the secretion of 269 
its gene product. In conclusion, glucagon like peptide-1 infusion or feeding fat did not decrease 270 
dry matter intake or affect hypothalamic neuropeptide mRNA concentrations of sheep. 271 
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Table 1  338 
Formulation and chemical composition of the control diet and fat supplemented diets  339 
Item 
Diet (% of DM) 
Control and 
GLP-1z Fat 
Ingredients   
Alfalfa meal, 17% CP 20.00 20.00 
Soy hulls 20.00 20.00 
Ground corn 48.59 43.90 
Ca salts of palm oily - 6.00 
Soybean meal, 48% CP 8.00 8.09 
Urea 0.50 0.60 
Limestone 1.50 - 
Monosodium phosphate 0.05 0.05 
Trace mineral salts 0.50 0.50 
Vitamin A (30,000 IU/g) 0.01 0.01 
Vitamin D (3,000 IU/g) 0.01 0.01 
Vitamin E (44 IU/g) 0.05 0.05 
Selenium (200 mg/g) 0.09 0.09 
Animal-vegetable fat 0.30 0.30 
Ammonium chloride 0.40 0.40 
Chemical composition   
NDF 28.01 24.68 
CP 14.96 15.75 
Ash 5.92 5.16 
Total fatty acids 2.88 7.25 
 340 
z  Intravenous GLP-1infused 341 
y Megalac®, Church and Dwight Co., Inc., Princeton, NJ.342 
Table 2. Primer sequences used for the reverse transcriptase quantitative PCR 343 
 344 
Item 
Forward 
Sequence, 5’ to 3’  
Reverse 
Sequence, 5’ to 3’ 
NPYz tcagcgctgcgacactacat gcagagactggagagcaagt 
AgRPz cctgaggaagccttattcct caggattcatgcagccttac 
POMCz agtgtcaggacctcaccacg gctgctgctaccattccga 
z  NPY = Neuropeptide Y; AgRP = Aguti-related peptide; POMC = Proopiomelanocortin. 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
 355 
 356 
 357 
 358 
Table 3 359 
Dry matter intake (DMI), metabolizable energy intake (MEI) and digestibility of diet 360 
components  in growing wethers fed a control diet, the control diet plus 6% Ca salts of palm oil 361 
(6% Fat), or infused intravenously with 0.155 µg/kg BW/day of GLP-1. 362 
 363 
 364 
* Differs from control, P < 0.05.  365 
† Differs from control, P < 0.10.  366 
Z Time by treatment interaction (P < 0.05). 367 
  368 
Item 
Treatments 
S.E. P Control 6% Fat GLP-1 
Lambs per treatment 11 12 11   
DMI (kg/d)z 1.33 1.29 1.35 0.07 0.83 
MEI (Mcal/d) 3.44 3.73 3.58 0.19 0.68 
Digestibility (%)      
Dry matter 69.51 69.26 71.51 0.96 0.21 
Organic matter 53.34 50.79 49.74 1.45 0.22 
Neutral detergent fibre 48.38 40.31* 52.39† 1.64 0.01 
Crude protein 65.44 67.76 67.30 1.00 0.24 
Fatty acids 82.09 85.70 80.02 2.00 0.17 
Table 4  369 
Plasma hormone and metabolite concentration in growing wethers fed a control diet, the control 370 
diet plus 6% Ca salts of palm oil (6% Fat), or infused intravenously with 0.155 µg/kg BW/day of 371 
GLP-1. Due to lack of time by treatment interaction values represent average of day 1, 4 and 6.  372 
 373 
 374 
Item 
Treatments 
S.E. 
P 
Control 6% Fat GLP-1 Trtz Time TxTz 
Lambs per treatment 11 12 11     
Insulin (pM) 312 270 270 23 0.34 0.84 0.82 
GLP-1z (pM) 23 34* 25 2 0.01 0.44 0.50 
Glucose (mM) 3.63 3.55 3.57 0.09 0.73 0.22 0.20 
NEFAz (mM) 49.54 77.54* 58.58 8.81 0.08 0.97 0.46 
 375 
 376 
z  Trt= treatment effect; TxT = time by treatment interaction effect; GLP-1= glucagon-like 377 
peptide-1 (7-36) amide; NEFA= non esterified fatty acid. 378 
* Differs from control, P < 0.05. 379 
 380 
 381 
382 
Table 5  383 
Hypothalamic concentrations of mRNA in growing wethers fed a control diet, the control diet 384 
plus 6% Ca salts of palm oil (6% Fat), or infused intravenously with 0.155 µg/kg BW/day of 385 
GLP-1. 386 
 387 
Itemz 
Treatments 
S.E. P Control 6% Fat GLP-1 
Lambs per treatment 11 12 10   
NPY 0.786 0.216 0.137 0.33 0.37 
AgRP 0.200 0.031 0.046 0.09 0.40 
POMC 0.311 0.168 0.084 0.09 0.25 
 388 
 389 
z Concentrations of mRNA (relative to cyclophilin B) for neuropeptide Y (NPY), agouti related 390 
peptide (AgRP), and proopiomelanocortin (POMC). 391 
 392 
  393 
 394 
 395 
 396 
 397 
Figure 1 398 
Dry matter intake (DMI) over 6 days  in wethers fed a diet without supplemental fat (◊) a diet 399 
with the addition of 6% Ca salts of palm oil (□) or the control diet  and infused with 0.155 µg/kg 400 
BW/day of GLP-1 (7-36) amide (▲). Time by treatment interaction (P < 0.05). 401 
  402 
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 404 
Figure 2 405 
Plasma concentration of glucagon like peptide-1 (7-36) amide (GLP-1) over 6 days  in wethers 406 
fed a diet without supplemental fat (◊) a diet with the addition of 6% Ca salts of palm oil (□) or 407 
the control diet  and infused with 0.155 µg/kg BW/day of GLP-1 (7-36) amide (▲). Treatment 408 
effect (P < 0.01), time by treatment interaction (P = 0.50). 409 
 410 
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